CD33PAN CAR T / Fred Hutchinson Cancer Center - LARVOL DELTA

Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. (PubMed, Mol Ther Oncol) - "CD33PAN moieties were detected at a higher frequency on human leukemic stem cells, and CD33PAN CAR T cells had greater in vitro efficacy against primary human AML cells. Together, our studies demonstrate improved efficacy with CAR T cells binding CD33 close to the cell membrane, providing the rationale to investigate CD33PAN CAR T cells further toward possible clinical application."

CAR T-Cell Therapy • IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy (ASH 2021) - "Similar constructs using scFvs from 2 different V-set domain-targeting CD33 antibodies, including hP67.6 (My96; used in gemtuzumab ozogamicin), were generated for comparison. Targeting the membrane proximal domain of CD33 enhances the anti-leukemic potency of CAR T cells. Our data provide the rationale for the further development of CD33 PAN CAR T cells toward clinical testing."

CAR T-Cell Therapy • IO biomarker • Acute Myelogenous Leukemia • Oncology • CD19 • CD33 • CD8 • IL15 • IL7